Last reviewed · How we verify
Fosfomycin Trometamol Salt
Fosfomycin Trometamol Salt, marketed by Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina, is an established antibiotic with a key composition patent expiring in 2028. The drug's primary strength lies in its unique mechanism of action, which differentiates it from other antibiotics in the market. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | Fosfomycin Trometamol Salt |
|---|---|
| Also known as | Monurol |
| Sponsor | Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- FOsfomycin for Male Urinary Tract Infection (PHASE3)
- Therapeutic Options for CRAB (PHASE4)
- Preoperative Prophylactic Fosfomycin Trometamol Versus 5-day Levofloxacin in Prevention of Postpercutaneous Nephrolithotomy Infectious Complications and Sepsis. (NA)
- Safety and Efficacy of a Weekly Oral Cyclic Antibiotic Programme in the Prevention of Urinary Tract Infection on Neurological Bladder (PHASE4)
- Pivmecillinam as Oral Step-Down Treatment for Escherichia Coli Febrile Urinary Tract Infection Versus Standard of Care (PHASE4)
- NextGen - Clinical Implication of Next Generation Sequencing (PHASE4)
- PK/PD Relationship of CAZ/AVI and FOS in the Treatment of Patients With Infections Due to CRE
- A Combination Therapy With Ceftazidime and Fosfomycin Will be Compared to Ceftazidime Alone in Hospitalized Adult Patients With Suspected Severe Gram-negative Bacterial Infections (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: